Litigation Details for BIOGEN INTERNATIONAL GMBH v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2019)

BIOGEN INTERNATIONAL GMBH v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2019)

Docket		Date Filed	2019-02-15
Court	District Court, D. New Jersey	Date Terminated	2019-04-17
Cause	35:271 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	None	Referred To	Lois H. Goodman
Patents	6,509,376; 7,320,999; 7,619,001; 8,399,514
Link to Docket	External link to docket

Details for BIOGEN INTERNATIONAL GMBH v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-02-15				External link to document
2019-02-14	1		against Zydus for patent infringement of U.S. Patent No. 6,509,376 (“the ’376 patent”), in Biogen International…for patent infringement of U.S. Patent No. 7,619,001 (“the ’001 patent”) arising under the patent laws…against Zydus for patent infringement of U.S. Patent Nos. 8,399,514 (“the ’514 patent”) and 7,320,999 …Delaware against Zydus for patent infringement of the ’514 patent and the ’999 patent in a case captioned …21 C.F.R. § 314.95(c) as to the ’514 patent and the ’999 patent. The First New Jersey Suit and the First	External link to document

Biogen International GmbH v. Zydus Pharmaceuticals: Tecfidera Patent Litigation Summary

Last updated: September 29, 2026

Biogen International GmbH sued Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of New Jersey after Zydus submitted an abbreviated new drug application seeking approval for generic dimethyl fumarate delayed-release capsules, the active pharmaceutical ingredient in Tecfidera. The case, No. 3:19-cv-05987, was a Hatch-Waxman patent action based on Zydus’s Paragraph IV certification.

The dispute concerned Biogen patents covering dimethyl fumarate treatment regimens for multiple sclerosis. The case did not produce a publicly reported merits judgment invalidating or upholding the asserted patents. The action was resolved and dismissed rather than proceeding to a final trial judgment.

What drug was at issue in Biogen v. Zydus?

The litigation involved generic dimethyl fumarate delayed-release capsules, marketed by Biogen as Tecfidera.

Item	Information
Reference drug	Tecfidera
Active ingredient	Dimethyl fumarate
Dosage form	Delayed-release oral capsules
Reference sponsor	Biogen Idec Inc. and affiliated Biogen entities
Proposed generic sponsor	Zydus Pharmaceuticals (USA) Inc.
Therapeutic use	Relapsing forms of multiple sclerosis
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of New Jersey
Case number	3:19-cv-05987
Filing year	2019

FDA approved Tecfidera in 2013 for relapsing forms of multiple sclerosis. The approved regimen is 120 mg twice daily for the first seven days, followed by 240 mg twice daily. The product is supplied as delayed-release capsules to reduce gastrointestinal exposure to dimethyl fumarate in the stomach.[1]

What patents did Biogen assert against Zydus?

Public case materials identify Biogen’s Tecfidera patent estate as the basis for the action, including patents directed to dimethyl fumarate treatment methods and dosage regimens. The principal patents associated with this litigation included U.S. Patent Nos. 8,399,514 and 8,759,393.

Patent	General subject matter	Relevance to Tecfidera
U.S. 8,399,514	Treatment of multiple sclerosis with dimethyl fumarate	Dosage and treatment regimen claims
U.S. 8,759,393	Dimethyl fumarate treatment methods	Method-of-use protection
U.S. 7,619,001	Fumaric acid ester treatment methods	Earlier Tecfidera-related patent; expiration reduced its post-2020 commercial value

The ’514 patent was particularly important in the broader Tecfidera litigation. Its claims covered treatment of multiple sclerosis using a total daily dose of 480 mg of dimethyl fumarate. The patent was later found invalid for obviousness in separate litigation involving Mylan, and the Federal Circuit affirmed that judgment.[2]

The Zydus case should not be treated as an independent confirmation that these patents were valid. The case ended without a public final judgment on infringement or validity.

What was Zydus’s Paragraph IV challenge?

Zydus submitted an ANDA seeking approval to market generic dimethyl fumarate delayed-release capsules before expiration of Biogen’s listed patents. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

Biogen’s complaint triggered the Hatch-Waxman litigation framework. Under the statute, filing a patent-infringement action within 45 days after receiving a Paragraph IV notice generally creates a 30-month stay of FDA approval, subject to statutory exceptions and court action.[3]

The Zydus filing therefore created two separate legal issues:

1. Whether the proposed Zydus product would infringe Biogen’s patent claims.
2. Whether the asserted claims would survive validity challenges, particularly obviousness and written-description attacks.

The public record does not show a final court determination resolving either issue in the Zydus action.

What was the litigation timeline?

The core procedural timeline is as follows:

Date or period	Event
2013	FDA approved Tecfidera for relapsing forms of multiple sclerosis
2019	Zydus submitted an ANDA with Paragraph IV certifications directed to Tecfidera-related patents
September 2019	Biogen filed Civil Action No. 3:19-cv-05987 in the District of New Jersey
2019-2021	The parties litigated the Hatch-Waxman patent dispute
Case resolution	The action was dismissed pursuant to an agreed resolution rather than a public merits judgment
2022	Federal Circuit affirmed invalidity of Biogen’s ’514 patent in separate litigation involving Mylan
2023 onward	Generic dimethyl fumarate competition expanded following developments in separate Tecfidera patent litigation

The case’s dismissal means that the docket does not supply a binding judgment on whether Zydus’s product infringed the asserted claims. It also does not establish a public claim-construction ruling, summary-judgment decision, or trial verdict against Zydus.

Was there a settlement agreement between Biogen and Zydus?

The action was resolved through a negotiated disposition. The publicly available case record reflects dismissal of the claims, but the commercial terms of any settlement were not made part of the public merits record.

A Hatch-Waxman settlement can address:

• The date on which the generic company may launch.
• Whether the generic may launch through an authorized-generic arrangement.
• Allocation of patent litigation costs.
• Restrictions on product design or indications.
• Covenants not to sue.
• Royalty or supply arrangements.
• Treatment of future patents or regulatory changes.

No public source cited in the case record establishes a definitive Zydus launch date, royalty rate, or authorized-generic structure. The dismissal therefore should not be interpreted as a public concession by either party regarding patent validity or infringement.

Did Biogen win or lose the Zydus case?

Neither party received a public merits victory in the Zydus action.

Biogen obtained dismissal of the specific case, which ended the litigation against Zydus in that docket. Zydus did not receive a publicly reported judgment holding the asserted patents invalid or noninfringed. At the same time, Biogen did not obtain a final injunction or a trial judgment confirming infringement.

The later invalidation of the ’514 patent in separate Mylan litigation materially weakened Biogen’s broader Tecfidera patent position. The Federal Circuit affirmed the finding that the asserted ’514 claims were obvious.[2] That decision had broader commercial consequences because an invalidity judgment against a key Orange Book patent can affect other ANDA applicants asserting similar Paragraph IV positions, although collateral-estoppel effects depend on the parties, claims, issues, and procedural posture.

What is the Orange Book status of Tecfidera?

Tecfidera’s Orange Book protection consisted primarily of method-of-use patents rather than a conventional small-molecule composition patent that would remain in force for the full commercial life of the product.

The principal Orange Book issues were:

• Method-of-use claims covering dimethyl fumarate treatment.
• Dosage-regimen claims directed to the approved 480 mg daily dose.
• Patent expiration dates extending beyond the initial 30-month stay period.
• Paragraph IV challenges by generic manufacturers.
• Separate litigation over the validity of the ’514 patent.

The ’514 patent had a listed expiration in 2028, subject to patent-term adjustment and any applicable regulatory exclusivity calculations. Its invalidation substantially reduced the practical blocking effect of that patent despite the nominal expiration date.

The older ’001 patent had an expiration date around 2020 and was therefore less significant to the 2019-2021 generic litigation. The commercial dispute centered on later patents, particularly the ’514 patent and related Tecfidera method patents.[4]

How did the Zydus case compare with Biogen’s Mylan litigation?

The Zydus and Mylan cases involved the same broader Tecfidera patent estate, but they produced different legal outcomes.

Issue	Biogen v. Zydus	Biogen v. Mylan
Product	Generic dimethyl fumarate delayed-release capsules	Generic dimethyl fumarate delayed-release capsules
Legal basis	Hatch-Waxman Paragraph IV action	Hatch-Waxman Paragraph IV action
Principal patent focus	Tecfidera method and dosage patents	Particularly the ’514 patent
Public merits ruling	No final merits judgment reported	’514 patent held invalid for obviousness
Appellate result	No comparable merits appeal identified	Federal Circuit affirmed invalidity
Commercial effect	Case-specific resolution	Weakened Biogen’s broader patent barrier to generic entry

The Mylan judgment became more important to the market than the Zydus dismissal because it produced a precedential appellate decision concerning the validity of the ’514 patent. A settlement in one ANDA case can preserve commercial uncertainty, while a final invalidity ruling can change the risk analysis for multiple generic applicants.

What patent litigation affected generic Tecfidera entry?

Biogen faced multiple ANDA challenges to Tecfidera patents. The major legal pressure points were:

Invalidity based on obviousness

The central question was whether it would have been obvious to use dimethyl fumarate at the claimed 480 mg daily dose for treating multiple sclerosis. The district court concluded that the asserted ’514 claims were obvious, and the Federal Circuit affirmed.[2]

Written-description and claim-scope disputes

The litigation also involved whether the patent specification adequately supported the claimed dosage regimen and whether the claims reached the proposed generic products. These issues are common in method-of-use litigation where the patent claims a specific clinical regimen rather than the active ingredient itself.

Patent-term and regulatory timing

Even an unexpired patent does not always prevent market entry if the patent is invalidated, disclaimed, delisted, or otherwise removed as a practical barrier. Conversely, a settlement can delay market entry beyond the date that would follow from patent litigation alone.

Product-specific infringement

Zydus’s proposed labeling, dosage strengths, manufacturing process, and ANDA certifications would have affected the infringement analysis. An ANDA applicant may challenge patents while attempting to avoid infringement through a section viii statement or a carved-out label, depending on the patent claims and FDA labeling.

What FDA regulatory status applied to the Zydus product?

Zydus pursued FDA approval through the ANDA pathway. Approval of a generic dimethyl fumarate product requires demonstration of pharmaceutical equivalence and bioequivalence to Tecfidera, along with compliance with current good manufacturing practice requirements.

The patent case did not itself establish final FDA approval. Patent litigation and FDA review are separate processes:

• FDA evaluates safety, efficacy equivalence, quality, labeling, and manufacturing.
• The district court evaluates patent infringement and validity.
• A Paragraph IV lawsuit may delay FDA approval through the statutory 30-month stay.
• A settlement may establish a contractual launch date that differs from the nominal patent expiration date.

No public case disposition by itself proves that Zydus had immediate approval or an unrestricted right to launch.

How strong was Biogen’s patent estate after the Zydus litigation?

Biogen’s Tecfidera patent estate was commercially meaningful but legally vulnerable.

Strengths

• The patents covered the approved clinical dosage regimen.
• The claims were listed in the Orange Book.
• Paragraph IV litigation imposed significant timing and cost burdens on generic applicants.
• The patent terms extended well beyond Tecfidera’s 2013 FDA approval.

Weaknesses

• The core ’514 dosage claims were invalidated in separate litigation.
• The estate relied heavily on method-of-use claims rather than broad composition claims.
• Multiple generic applicants attacked the same patents.
• Patent expiration dates alone overstated the practical exclusivity period after the invalidity ruling.
• Settlement outcomes limited the amount of public precedent available from individual cases such as Zydus.

For investors and licensing parties, the key distinction is between nominal patent life and enforceable exclusivity. The ’514 patent’s nominal 2028 expiration did not preserve equivalent commercial protection after the Federal Circuit affirmed invalidity.

What generic launch risks existed for Biogen?

Biogen faced several generic-entry scenarios:

1. Early launch after settlement. Zydus could receive a contractually defined launch date.
2. Launch after invalidity litigation. Other applicants could rely on the Mylan judgment to pursue earlier entry.
3. At-risk launch. A generic company could launch before all patent disputes were resolved, accepting potential damages exposure.
4. Delayed launch. A settlement could defer entry until a negotiated date.
5. Multiple-generic competition. Once the principal patent barrier weakened, several ANDA applicants could enter in a compressed period.

Generic competition would affect Tecfidera net sales, pricing, rebate economics, and Biogen’s ability to shift patients toward other fumarate products, including Vumerity. The financial effect would depend on the number of approved competitors, launch timing, generic pricing, payer substitution, and the degree of overlap between Tecfidera and alternative dimethyl fumarate presentations.

Key Takeaways

• Biogen sued Zydus in 2019 over a Paragraph IV ANDA for generic dimethyl fumarate delayed-release capsules.
• The dispute involved Biogen’s Tecfidera method-of-use and dosage-regimen patent estate, including U.S. Patent Nos. 8,399,514 and 8,759,393.
• The Zydus action ended without a publicly reported final judgment on infringement or validity.
• The case resolution did not publicly establish a Zydus launch date or settlement economics.
• The later Federal Circuit affirmance of the ’514 patent’s invalidity in separate Mylan litigation weakened Biogen’s broader Tecfidera exclusivity position.
• Tecfidera’s nominal patent expiration dates overstated the practical strength of the estate after the key dosage patent was invalidated.
• FDA approval, patent enforcement, and generic launch timing remained separate legal and regulatory questions.

FAQs

What was Biogen’s product in the Zydus lawsuit?

The reference product was Tecfidera, an FDA-approved delayed-release dimethyl fumarate capsule for relapsing forms of multiple sclerosis.

Did Zydus receive FDA approval for generic Tecfidera?

The patent docket does not itself establish the final FDA approval status of a Zydus product. FDA approval is separate from the district court litigation.

Did Biogen obtain an injunction against Zydus?

No publicly reported final injunction or merits judgment against Zydus appears in the case disposition. The action was dismissed after negotiated resolution.

Was the Tecfidera ’514 patent enforceable after the Mylan decision?

The Federal Circuit affirmed the finding that the ’514 patent claims at issue in the Mylan litigation were invalid for obviousness. That ruling materially reduced the patent’s practical ability to block generic entry.

Did the Zydus settlement authorize an early generic launch?

The public disposition does not establish the commercial terms of the resolution or a definitive Zydus launch date.

References

1. U.S. Food and Drug Administration. (2013). Tecfidera prescribing information.
2. Biogen International GmbH v. Mylan Pharmaceuticals Inc., 18 F.4th 1333 (Fed. Cir. 2021).
3. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. Biogen International GmbH v. Zydus Pharmaceuticals (USA) Inc., No. 3:19-cv-05987, U.S. District Court for the District of New Jersey.